VisionSense raises $8m

The company already has sales of its 3D Stereoscopic Vision System endoscope in the US and Europe.

3D minimally invasive surgical solutions developer VisionSense Ltd. has raised $8 million from Volcano Capital Ltd., Wheatley Capital, TechnoPlus Ventures Ltd. (TASE:TNPV), and other investors.

Founded as EnVision in 1998, VisionSense is now at the market penetration stage for its product, Visionsense Stereoscopic Vision System endoscope, which provides a 3D image for diagnosis or navigation for minimally invasive surgical procedures.

VisionSense already has sales in the US and Europe, and is planning an organized penetration of the market, either via its own marketing staff, or through distributors. The proceeds from the round are slated for this purpose, as well as for the development of new products.

Lewis Pell invested in VisionSense in 2004. Pell and Prof. Shlomo Ben-Haim have invested in dozens of start-ups and made more than $500 million in exits, including in Biosense, Instent, Disc-o-Tech Ltd., and X-Technologies.

Other shareholders in VisionSense include GlenRock Israel, Star Ventures, abd Shalom Equity Fund.

Published by Globes [online], Israel business news - www.globes-online.com - on October 18, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters